Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 28, 2022 13:48 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the...
November 10, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments,...
November 08, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results...
October 26, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials...
October 13, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials...
September 09, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate...
August 25, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine

Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis ULTIMATE I and II...
August 08, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments,...
August 05, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update

NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 AM ET to discuss results for...
June 27, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology

NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II...